Takeda Agrees to Pay $2.3 Billion to Settle Actos Cases
This article is for subscribers only.
Takeda Pharmaceutical Co. said it will pay $2.37 billion to resolve U.S. lawsuits accusing the company of hiding its Actos diabetes medicine’s cancer risks.
Takeda will put the money into a settlement fund if 95 percent of those with claims against Asia’s largest drugmaker agree to join the accord, Takeda officials said in a statement.